Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: A live webcast will be available on the Events and Presentations link on the Investors page of the ...

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $75 from $60 and keeps a Buy rating on the shares following the Q4 report. The commercialization of Verona’s sole ...